Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson’s Disease

Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson’s Disease

Background. Wnt/β-catenin signaling has been reported to exert cytoprotective effects in a cellular model of Parkinson’s disease (PD). Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of PD, and excitatory amino acid transporters (EAATs) play a predominant role in cleari...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lei Wei, Chuan Chen, Li Ding, Mingshu Mo, Jing Zou, Zhenze Lu, Haiyan Li, Haotian Wu, Yongqiang Dai, Pingyi Xu, Zhengqi Lu
Format:	Article
Language:	English
Published:	Wiley 2019-01-01
Series:	Neural Plasticity
Online Access:	http://dx.doi.org/10.1155/2019/1247276
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Retraction Note: Xiaoyaosan exerts antidepressant-like effects by regulating the functions of astrocytes and EAATs in the prefrontal cortex of mice
by: Yan Liu, et al.
Published: (2025-01-01)

Astrocytic YAP prevents the glutamate neurotoxicity by upregulation of EAAT2 expression and promotes the gain of stemness in astrocytes in ischemic stroke mice
by: Xuan Luo, et al.
Published: (2025-07-01)

NaHS modulates astrocytic EAAT2 expression to impact SNI-induced neuropathic pain and depressive-like behaviors
by: Man-Man Qi, et al.
Published: (2025-01-01)

Dopaminergic Modulation of Prospective Memory in Parkinson’s Disease
by: Alberto Costa, et al.
Published: (2008-01-01)

Effect of dopaminergic therapy on lacrimation in Parkinson's disease
by: A. A. Pilipovich, et al.
Published: (2023-12-01)

Impact of electro-acupuncture on EAAT2 and NMDAR-2B expression in goats with visceral hypersensitivity
by: Adnan Hassan Tahir, et al.
Published: (2024-12-01)

Downregulation of EAAT-2 impairs chronic neuropathic pain via increasing of plasma glutamate after herpes zoster infection
by: Li-Na Lu, et al.
Published: (2025-07-01)

Dysregulation of protein degradation and alteration of secretome in α-synuclein-exposed astrocytes: implications for dopaminergic neuronal dysfunction
by: Aishwarya Raj, et al.
Published: (2024-12-01)

Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
by: Anders H. Andersen, et al.
Published: (2015-01-01)

Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction
by: Luciana Ulhôa Guedes, et al.
Published: (2012-11-01)

Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.
by: Alisdair McNeill, et al.
Published: (2013-01-01)

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease
by: Xiaoqin He, et al.
Published: (2025-01-01)

BMAL1 in Astrocytes: A Protective Role in Alzheimer’s and Parkinson’s Disease
by: David Brash-Arias, et al.
Published: (2025-01-01)

Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson’s Disease
by: Yanqin Wang, et al.
Published: (2017-01-01)

Hybrid virtual screening and molecular dynamics approach for identification of allosteric modulator of EAAT2
by: Chennu Manisha, et al.
Published: (2024-10-01)

Dyrk1a Phosphorylation of α-Synuclein Mediating Apoptosis of Dopaminergic Neurons in Parkinson’s Disease
by: Yuxuan Yong, et al.
Published: (2023-01-01)

The Effect of Dopaminergic Therapy in Parkinson’s Disease: A Graph Theory Analysis
by: Karthik Siva, et al.
Published: (2025-04-01)

NF-κB-mediated EAAT3 upregulation in antioxidant defense and ferroptosis sensitivity in lung cancer
by: Donghua Wen, et al.
Published: (2025-02-01)

The Effect of Dopaminergic Medication on Joint Kinematics during Haptic Movements in Individuals with Parkinson’s Disease
by: Kuan-yi Li, et al.
Published: (2017-01-01)

Dopaminergic modulation of behavioral and electrocortical markers of interpersonal performance monitoring in Parkinson’s Disease
by: Vanessa Era, et al.
Published: (2025-08-01)

Correction: NF-κB-mediated EAAT3 upregulation in antioxidant defense and ferroptosis sensitivity in lung cancer
by: Donghua Wen, et al.
Published: (2025-04-01)

Oligodendrocyte-astrocyte crosstalk in Parkinson’s disease mediates neuronal ferroptosis via the FGF signaling pathway
by: Sen Zhang, et al.
Published: (2025-05-01)

Correlation of Dopaminergic Denervation and the Progression of Autonomic Dysfunctions in Different Clinical Subtypes of Parkinson’s Disease
by: Eun Hye Jeong, et al.
Published: (2021-01-01)

Aberrant epigenome in iPSC‐derived dopaminergic neurons from Parkinson's disease patients
by: Rubén Fernández‐Santiago, et al.
Published: (2015-10-01)

REM density in Parkinson’s disease: association with motor, cognitive, autonomic function, and dopaminergic medication
by: Andrew Dagay, et al.
Published: (2025-07-01)

Unraveling the mystery: How autophagy deficiency in dopaminergic neurons drives human Parkinson’s disease
by: Sachiko Noda, et al.
Published: (2025-07-01)

Electroconvulsive therapy promotes striatal dopaminergic recovery in a mouse model of Parkinson’s disease
by: Anika Frank, et al.
Published: (2025-01-01)

Urinary Dysfunction Is Associated with Nigrostriatal Dopaminergic Degeneration in Early and Untreated Patients with Parkinson’s Disease
by: Jing Wang, et al.
Published: (2020-01-01)

Longitudinal Assessment of Parkinson’s Motor Symptoms and Dopaminergic Dysfunction Patterns Using DaTSCAN
by: Amir Hossein Najmi, et al.
Published: (2025-01-01)

Astrocytes-associated research in Parkinson’s disease: an explored trends analysis
by: Yan-Jun Chen, et al.
Published: (2025-03-01)

Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson’s Disease
by: Rayul Wi, et al.
Published: (2020-01-01)

The Neuroprotective Mechanism of Low-Frequency rTMS on Nigral Dopaminergic Neurons of Parkinson’s Disease Model Mice
by: Qiaoyun Dong, et al.
Published: (2015-01-01)

Gardenia-derived extracellular vesicles exert therapeutic effects on dopaminergic neuron apoptosis-mediated Parkinson’s disease
by: Wen Chen, et al.
Published: (2025-07-01)

Temporal evolution of microstructural integrity in cerebellar peduncles in Parkinson’s disease: Stage-specific patterns and dopaminergic correlates
by: Chentao He, et al.
Published: (2024-01-01)

Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression
by: Ji Hun Kim, et al.
Published: (2025-02-01)

A Case of Painless Legs and Moving Toes Syndrome in Parkinson’s Disease Responsive to Dopaminergic Therapy
by: Sumihiro Kawajiri, et al.
Published: (2016-01-01)

Bilateral functional connectivity of the basal ganglia in patients with Parkinson's disease and its modulation by dopaminergic treatment.
by: Simon Little, et al.
Published: (2013-01-01)

Relative sparing of dopaminergic terminals in the caudate nucleus is a feature of rest tremor in Parkinson’s disease
by: Marcelo D. Mendonça, et al.
Published: (2024-11-01)

The Role of Astrocytes in Poststroke Rehabilitation
by: Ying Han, et al.
Published: (2025-06-01)

Formation of CSE-YAP complex drives FOXD3-mediated transition of neurotoxic astrocytes in Parkinson’s disease
by: Rong-Xin Zhu, et al.
Published: (2024-12-01)